The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2804 participants.
Also called NCT07381803
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,804 participants
- Registry
-
NCT07381803
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07381803. Randomized; triple masking; primary purpose treatment. Start 2025-01-27 (actual); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction
- Condition
- Zhejiang University
- Intervention (Drug)
- Fexofenadine 60 Mg Oral Tablet
- Intervention (Drug)
- Placebo
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Record details
- Record id
cardio:ct-nct07381803- Content hash
11bceffd667ad7680d3a545c2411fa4b59c770eb5274d1b79b98c9a3f334962b